Pre-Open Stock Movers 08/03: (OTLK) (TBIO) (HOLI) Higher; (CLX) (RNA) (KOPN) Lower (more...)

Driven Brands (DRVN) Prices 12M Share Offering at $29.50/sh

Driven Brands Holdings Inc. (Driven Brands or the Company) (NASDAQ: DRVN), today announced the pricing of the underwritten secondary public offering of 12 million shares of Driven Brands common stock by Driven Equity LLC and RC IV Cayman ICW Holdings LLC (together the Selling Stockholders), each of which is a related entity of Roark Capital Management, LLC at a price of $29.50 per share. The Selling Stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock. Driven Brands is not selling any shares of common stock in the offering and... More

JPMorgan Upgrades Under Armour, Inc. (UAA) to Overweight

JPMorgan analyst Matthew R. Boss upgraded Under Armour, Inc. (NYSE: UAA) from Neutral to Overweight with a price target of $30.00 (from $25.00).

The analyst comments "We are upgrading UAA to Overweight establishing a $30 Dec '22 price target given the combination of (i) Micro P/L Inflection: +12%... More

ZoomInfo Technologies Inc. (ZI) Upsizes Secondary Offering to 27M Shares from 20M Shares

ZoomInfo Technologies Inc. (NASDAQ: ZI) today announced an upsizing of the previously announced underwritten secondary offering by certain selling stockholders of ZoomInfo, including investment funds affiliated with TA Associates (TA), The Carlyle Group (Carlyle) and 22C Capital LLC (22C Capital) and an entity affiliated with ZoomInfos co-founders (together with TA, Carlyle and 22C Capital, the Selling Stockholders), to 27,000,000 shares of ZoomInfos Class A common stock pursuant to ZoomInfos... More

Avidity Biosciences Inc. (RNA) Prices 8M Share Offering at $18/sh

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of... More

Take-Two Interactive (TTWO) PT Lowered to $230 at Stifel

Stifel analyst Drew E. Crum lowered the price target on Take-Two Interactive (NASDAQ: TTWO) to $230.00 (from $237.00) while maintaining a Buy rating.

The analyst commented, "Take-Two reported its FY1Q which featured y/y declines (as anticipated), reflecting tough comps and an uptick in... More

Outlook Therapeutics, Inc. (OTLK) Phase 3 Data Supports Approval - Analyst

Earlier today, Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 / LYTENAVA (bevacizumab) - the companys lead drug candidate for treatment of neovascular... More

SolarEdge Technologies (SEDG) PT Raised to $280 at Canaccord Genuity

Canaccord Genuity analyst Jonathan Dorsheimer raised the price target on SolarEdge Technologies (NASDAQ: SEDG) to $280.00 (from $260.00) while maintaining a Hold rating following earnings after the close.

Outlook Therapeutics Incs. (OTLK) PT Raised to $6 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the price target on Outlook Therapeutics Incs. (NASDAQ: OTLK) to $6.00 (from $5.00) while maintaining a Buy rating.

ZoomInfo (ZI) Explodes on Strong Q2 Results and Guidance, Analysts Bulled Up with 10 PT Hikes

Shares of ZoomInfo Technologies (NASDAQ: ZI) are up about 12% in todays trading session after the company delivered better-than-expected Q2 results. At least ten Wall Street analysts raised their price target on the stock following the print.

The company recorded earnings of $0.05 per share, while adjusted EPS came in at $0.14 per share, ahead of analyst estimates of $0.12 per share. Revenue for the quarter came in at $174 million to again top the $162.4 million consensus from the Street.

"ZoomInfo delivered another record quarter, including the highest levels ever for both retention activity and customer... More